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summary 
The platelet-derived connective tissue activating peptide (CTAP-III) has been 
shown to be an important factor stimulating the metabolism and proliferation 
of human connective tissue cell strains, including synovial tissue cells. The 
quantities of CTAP-III affecting the cellular changes and the amounts in various 
biologic fluids and tissues are small. The objectives of this study were to devel- 
op a radioimmunoassay (RIA) for CTAP-III and to ascertain the specificities of 
the anti-CTAP-III sera reagents. The antisera were shown not to cross-react 
with a number of polypeptide hormones. However, two other platelet proteins, 
/3-thromboglobulin and low affinity platelet factor-4, competed equally as well 
as CTAP-III for antiCTAP- antibodies in the RIA system. Thus, the three 
platelet proteins are similar or identical with respect to those portions of the 
molecules constituting the reactive antigenic determinants. The levels of mate- 
rial in normal human platelet-free plasma that inhibited anti-CTAP-III--‘2sI- 
CTAP-III complex formation were determined to be 34 + 13 (S.D.) ng/ml. 
Introduction 
The connective tissue activating peptide- (CTAP-III) is a platelet derived 
polypeptide which causes increased glucose uptake, glycosaminoglycan syn- 
thesis, sulfate incorporation and lactate output in a number of fibroblast cell 
strains [l-4]. CTAP-III has also been shown to stimulate [ 3H] thymidine incor- 
* Correspondence should be addressed to Byron Anderson, Ph.D., Department of Biochemistry, North- 
western University Medical School, Chicago, IL 60611. U.S.A. 
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poration in cultured dermal and synovial fibroblasts, in chondrocytes and in an 
endothelial cell strain [1,3]. It is a low molecular weight protein (by amino 
acid analysis) and is cationic as determined by ion-exchange chromatography 
[ 21, isoelectric focusing [ 31 and immunoelectrophoresis [ 51. 
CTAP-III has been found to be antigenically similar to two other platelet- 
derived proteins, /3-thromboglobulin (PTG) and low affinity platelet factor 4 
(LA-PF4) by double immunodiffusion analyses [ 31. LA-PF4 has been shown to 
be very similar to CTAP-III in amino acid composition, molecular weight and 
biological activities, whereas PTG has a different molecular weight (8851 dal- 
tons per subunit) and does not demonstrate the biological activities of CTAP- 
III [3]. 
The studies presented here were begun in order to develop a sensitive 
immunoassay for the CTAP-III protein. The details of the radioimmunoassay 
(RIA) are presented together with data on the cross-reactivities of anti-CTAP- 
III sera and the levels of CTAP-III in normal human plasma. 
Materials and methods 
CTAP-III was purified to apparent homogeneity by previously published 
methods [2,3]. Briefly, outdated platelets were extracted with 10 vol of 5% 
1.25 mol/l HCl: 95% ethanol and CTAP-III material in the supernatant precipi- 
tated by the addition of 3 vol of acetone. The precipitate was dissolved in and 
dialyzed against 1.0 mol/l acetic acid containing 3.6% NaCl followed by dialysis 
against 0.5 mol/l phosphate buffer, pH 7.0, containing 0.15 mol/l NaCl. Pre- 
cipitates formed during dialysis were removed by centrifugation. The super- 
natant was chromatographed on Sephacryl S-200 and material eluting in the 
cytochrome C position were further purified on a CM-Sephadex C-50 ion- 
exchange resin equilibrated with 0.1 mol/l phosphate buffer, pH 6.0. CTAP- 
III was eluted from the CM-Sephadex using 0.25 mol/l NaCl in the phosphate 
buffer. The CTAP-III preparations used for immunizations and in the RIA 
experiments were homogeneous by the criteria of giving single protein bands 
following polyacrylamide gel electrophoresis in both sodium dodecyl sulfate 
and acid-urea systems. 
Anti-CTAP-III sera were produced in rabbits as previously described [ 51. The 
rabbits were given multiple intramuscular, subcutaneous and intraperitoneal 
injections of the purified CTAP-III emulsified in complete or incomplete 
Freund’s adjuvant on an approximately biweekly schedule. High titer and 
apparent high affinity anti-CTAP-III sera were obtained after the 4th immuniza- 
tion and the high titers of the antisera were maintained for over a year following 
booster immunizations. The anti-CTAP-III sera gave strong precipitin bands in 
double diffusion analyses against all human platelet extracts and human sera 
tested but were unreactive with platelet-poor plasma. The antisera were also un- 
reactive in double diffusion analyses with the polypeptides and growth factors 
listed below but gave single precipitin bands with OTC and LA-PF4 which fused 
with the CTAP-III precipitin band [ 3,5]. 
CTAP-III was radiolabeled by a modification of the method of Hunter and 
Greenwood [6] with all steps being carried out at 0-4°C. Approximately 5 Dug 
of lyophilized CTAP-III was dissolved in 90 ~1 of 0.67 mol/l NaPO, buffer, pH 
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7.0, and 1 mCi [“‘I]Na (Amersham Corp., Arlington Heights, IL) was added. 
Chloramine-T solution, 2 mg/ml, and sodium metabisulfite, 3 mg/ml, were 
made fresh in cold distilled water. Ten ,~l of chloramine-T solution was added 
followed 10 s later by 10 yl of sodium metabisulfite plus 100 ~1 each of 1 mol/l 
KI and 1% human serum albumin (HSA). The ‘251-CTAP-III was separated from 
free “‘1 on a 8.5 ml Sephadex G-25 column equilibrated and eluted with 0.1% 
HSA in 0.01 mol/l sodium phosphate buffer, pH 7.2, containing 0.154 NaCl 
(phosphate buffered saline, PBS) and 0.01% NaN+ 
Immunoreactive ‘251-CTAP-III was separated from non-reactive radiolabeled 
protein by reisolating it with an insolubilized anti-CTAP-III antibody using the 
method of Anderson et al. [7]. Briefly the procedure was as follows. One vol. 
of a saturated solution of ammonium sulfate was added to 2 vol of rabbit anti- 
CTAP-III serum, and the precipitate obtained was washed and concentrated to 
50 mg/ml of protein using an Amicon Centriflo cone (Amicon Corp., Lexing- 
ton, MA, mol. wt. exclusion of 25 000). Glutaraldehyde (25%) was added to a 
final concentration of 1% and the cross-linked insoluble proteins were washed 
with PBS. ‘251-CTAP-III from the Sephadex G-25 void volume was added to the 
glutaraldehyde cross-linked immunoadsorbent, and the mixture rotated for 2 h 
at 22°C and overnight at 4°C. The mixture was centrifuged at 1000 X g at 4°C 
for 15 min and the supernatant discarded. The pellet was washed 3 times with 
PBS. One ml of 0.1 mol/l glycine-HCl, pH 2.2, was then used to elute ‘251- 
CTAP-III from the immunoabsorbent. The glycine-HCl elution was repeated 
twice, the three supernatants combined, 1.5 ml of 1% HSA added, and the 
eluates dialyzed against PBS containing 0.5% NaN3 overnight at 4°C in Spectra- 
por tubing (Spectrum Medical Industries Inc., Los Angeles, CA, mol. wt. exclu- 
sion of 2000). 
Titrations of antisera were initially attempted using the Farr technique [8] 
for processing of RIA mixtures. It was found that 60--80% of the *2SI-CTAP-III 
precipitated at 50% ammonium sulfate concentration with both non-immunized 
rabbit sera or with the anti-CTAP-III sera, even though purified CTAP-III was 
soluble at the same ammonium sulfate concentration. Therefore, the ammo- 
nium sulfate method for separating free 1251-CTAP-III from antibody-bound 
1251-CTAP-III was not workable and the second antibody precipitation method 
[9] was utilized for precipitation of anti-CTAP-III antibody-‘2SI-CTAP-III 
complexes in the RIA. Appropriate dilutions of antisera were made in normal 
rabbit serum diluted 1 : 300 in 0.1% HSA-PBS containing 0.5 mol/l NaCl and 
0.01% NaN3. Three hundred ~1 of the diluted antiserum, unlabeled CTAP-III 
standards or other samples and lo-20 ~1 of 1251-CTAP-III (l-2 ng) were added 
to 12 mm X 75 mm polystyrene or glass tubes and the tubes incubated for 1 h at 
22°C. Sixty microliters of second antibody, goat anti-rabbit IgG (Miles-Yeda, 
Elkhart, IN), was then added to each tube and incubation was continued at 
37°C for 2 h followed by 30 min at 4°C. The tubes were centrifuged at 1500 X g 
for 30 min at 4°C and supematants removed. The pellets were counted and 
compared to the total counts added. The antiserum titers were defined as the 
dilutions of antisera binding 50% of the total 1251-CTAP-III added to the incu- 
bation mixtures. Non-specific binding of 1251-CTAP-III to the precipitates was 
determined using assay mixtures minus the anti-CTAP-III serum. All samples 
were run in duplicate or triplicate. 
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Several hormone polypeptides and growth factors were available from com- 
mercial and other sources for testing of inhibitory activities in the CTAP-III 
RIA. These experiments were performed to ascertain cross-reactivities with the 
anti-CTAP-III sera which would indicate possible structural homologies like 
those shown between insulin and nerve growth factor [lo]. Furthermore, 
because /3TG and LA-PF4 react with anti-CTAP-III sera in double immunodif- 
fusions analysis [ 3,5], the extent of cross-reactivities in the CTAP-III RIA sys- 
tem were also determined. The various growth factors and hormones used 
were: bovine insulin and parathyroid hormone (Eli Lilly Co., Indianapolis, IN), 
porcine glucagon (Lilly), human corticotropin and bovine thyrotropin (Armour 
Pharmaceuticals, Kankakee, IL), human chorionic gonadotropin (Aye& Co., 
Chicago, IL), human gastrin I and bradykinin (Chemical Dynamics), synthetic 
somatostatin (Sigma Chemical Co., St. Louis, MO), bovine fibroblast growth 
factor (FGF) and mouse epidermal growth factor (Collaborative Research, 
Waltham, MA), synthetic porcine luteinizing release hormone (Beckman Instru- 
ments, Palo Alto, CA), human prolactin (Calbiochem, La Jolla, CA), mouse 
nerve growth factor (obtained from Dr. J. Tomita), platelet factor-4 (PF4, ob- 
tained from Dr. M. Ginsberg), low-affinity platelet factor-4 (LA-PF4, supplied 
by Dr. S. Niewiarowski), and P-thromboglobulin (PTG, supplied by Dr. D. 
Pepper). 
Platelet-free plasma samples were collected from healthy volunteers. Venous 
blood was drawn into plastic syringes and gently transferred into chilled tubes 
containing EDTA and theophylline as anti-platelet release anticoagulants 
(Amersham Corp.). After centrifugation at 2500 Xg for 30 min at 4°C the 
supernatant was removed and frozen (-70°C) until assayed. 
A number of animal sera were tested for their ability to inhibit anti-CTAP- 
III--‘2SI-CTAP-III complex formation. These included human, rhesus monkey, 
horse, bovine, fetal calf, lamb, goat, mouse, rat, chicken and porcine sera. 
Blood was drawn into plastic syringes and allowed to clot in glass tubes for 1 h 
at 22°C. Serum was removed and centrifuged at 2500 X g for 30 min and stored 
at -70°C until used. 
Results 
The chloramine-T radioiodination procedure incorporated between 9.8 and 
21% of the available “‘1 into the CTAP-III. Specific activities were calculated 
to range from 4.3 to 12.8 pCi/pg CTAP-III. When the ‘251-CTAP-III prepara- 
tions reisolated from the anti-CTAP-III immunoadsorbent were tested in the 
double antibody RIA system the radiolabeled antigens were 80-90% bound by 
antiserum and only 20% or less of the total counts were non-specifically 
precipitated when using preimmune or normal rabbit serum. 
Titers of a number of rabbit anti-CTAP-III sera were determined. Anti- 
CTAP-III serum (week 28) was drawn 21 days after the 11th immunization and 
titered at a 1 : 60 000 dilution. Titers of weeks 32 and 12 sera drawn 21 and 7 
days after the 12th and 5th immunizations, respectively, had titers of 1 : 60 000 
and 1 : 17 000. The high titer antisera suggested that high affinity antibodies 
may have been produced in the rabbit. A second rabbit immunized with CTAP- 
III showed similar high titer antisera. 
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The curves for the inhibition of 1251-CTAP-IIIanti-CTAP-III antibody com- 
plex formation using CTAP-III, PTG and fibroblast growth factor (FGF) are 
shown in Fig. 1. Inhibition with unlabeled CTAP-III was seen at 0.5 ng and 
near-complete inhibition obtained with 10 ng. The same percent inhibition was 
obtained on a weight basis using LA-PF4 (data not shown). Also on a weight 
basis, /3TG inhibited the complex formation at lower amounts than when 
CTAP-III was used, and 95% inhibition was obtained with 10 ng of PTG in the 
incubation mixture. When the same data were plotted on a molar basis of the 
inhibitors (Fig. 2) using molecular weights of 9295 daltons for CTAP-III [3] 
and 8851 daltons for PTG [ll], the two inhibition curves were equivalent. 
FGF also competed for anti-CTAP-III-‘2SI-CTAP-III complex formation but 
much higher amounts were required, 1000 ng giving 77% inhibition. All other 
peptides and protein hormones listed in the Materials section showed no inhibi- 
tion with addition of 5 pg amounts to the RIA mixtures. 
The equivalent molar inhibitions of CTAP-III and /3TG in the RIA system 
suggested that those antibodies binding to 1251-CTAP-III under the conditions 
of the assay (1 : 40 000 dilution of antiserum) recognized similar or identical 
antigenic determinants of the two proteins. Furthermore, the finding that PTG 
completely inhibited the complex formation indicated that there was no anti- 
body specificity reactive with antigenic determinants unique to CTAP-III. In 
order to increase the probability of detecting possible antibodies specific for 
CTAP-III the RIA was conducted with the same antiserum diluted 1 : 300. As 
seen in Fig. 2, both PTG and CTAP-III gave equivalent inhibition values 
throughout the curve and both inhibited anti-CTAP-III--‘2SI-CTAP-III complex 
formation nearly completely. A series of double immunodiffusion analyses 
were also performed placing CTAP-III and PTG in adjacent antigen wells and 
allowing diffusion against anti-CTAP-III sera of both immunized rabbits from 
the early through the last weeks of immunization. In all cases single precipitin 
lines were obtained with both PTG and CTAP-III which fused with no detectable 
spurring. 
Fig. 1. Inhibition of anti-CTAP-III- I~~I-cTAP-III complex formation by CTAP-III. @TG and fibroblast 
growth factor. The RIA procedure was performed as described in the text. The anti-CTAP-III serum was 
used at a dilution of 1 : 60 000. Each point represents the mean of duplicate or triplicate determinations: 
(e), CTAP-III; (X). PTG; (0). fibroblast growth factor. 
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Fig. 2. Inhibition curves for CTAP-III and PTG plotted as the molar quantities of the inhibitors added to 
the incubation mixtures. The curves are drawn for anti-CTAP-III serum used at a dilution of 1 : 300: 
(.- - - - - -.), CTAP-III; (m- - - - - -a), PTG. 
The CTAP-III antigen was quantitated in 37 platelet-free human plasma 
specimens from healthy adults and the values ranged from 14 to 74 ng/ml. The 
calculated mean f S.D. was 34 + 13 ng/ml. In order to confirm the accuracy of 
the RIA system when measuring plasma CTAP-III antigen, it was necessary to 
evaluate the effect of plasma on the assay. Samples of platelet-free plasma 
(20 ~1 per assay mixture) produced no consistent change in the non-specific 
binding of ‘251-CTAP-III in the assay procedure. This suggested that human 
plasma lacks a specific CTAP-binding protein. Also, when known amounts of 
CTAP-III were added to a constant amount (15 ~1) of plasma (containing 0.52 
ng of antigenically reactive material), the inhibition curve was coincident with 
INHIBITOR, “Q 
Fig. 3. Lack of interference by plasma on anti-CTAP-III-l z 5 I-CTAP-III complex formation. A standard 
inhibition curve with CTAP-III (0) without plasma is compared to an inhibition curve of different 
amounts of CTAP-III added to 15 ~1 of plasma (0). The data point on the left (equal to 0.52 ng CTAP-III) 
is the 15 ~1 aliquot of the plasma sample without addition of purified CTAP-III. A plasma sample con- 
taining a relatively high amount (4.2 ng) of CTAP-III reactive material was diluted 1.3-, 2-and 4-fold and 
each dilution assayed (0). The point on the far right represents the 20 ~1 aliquot of undiluted plasma. 
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the CTAP-Ill inhibition curve without plasma added, (Fig. 3). Furthermore, a 
plasma sample containing a relatively large amount of anti-CTAP-Ill reactive 
material c.ould be diluted serially to give a coincident inhibition curve to that 
of CTAP-Ill (Fig. 3). 
A sample of human serum and fresh specimens of other animal sera (listed 
under “Materials”) were also tested for inhibition of the anti-CTAP-lll-‘Z’l- 
CTAP-Ill complex formation. The human serum contained approximately 
10 Mug/ml of CTAP-Ill reactive material. The rhesus monkey serum was also 
inhibitory in the RIA system whereas all other animal sera did not inhibitthe 
complex formation. 
Discussion 
The experimental details for the quantitation of CTAP-III by RIA have been 
presented. High nonspecific binding of 1251-CTAP-lll was observed with pro- 
tein precipitated from serum using the 50% concentration of ammonium sul- 
fate. Such binding may in part result from the cationic nature of the molecule 
or may be due to another serum protein which binds CTAP-Ill relatively 
specifically. Thus, high salt concentration (0.5 mol/l NaCl) was needed to 
reduce this non-specific binding of ‘251-CTAP-llI in the precipitation of anti- 
body-antigen complex step. It was also necessary to reisolate the ‘2Sl-CTAP-lll 
from an immunoadsorbent of glutaraldehyde-insolubilized anti-CTAP-Ill anti- 
bodies. Either certain iodination sites may alter tbe antigenic determinants of 
the molecule or the iodination conditions resulted in substantial denaturation. 
The disulfide bonds of CTAP-Ill are known to be important for the expression 
of biologic activity [2] and their reduction in the iodination procedure may 
also have altered the antigenic activity. 
Radioimmunoassays with several of the antiCTAP- sera diluted in the 
range of 1 : 20 000 to 1 : 60 000 gave comparable inhibition curves. The RIA 
was very sensitive with a workable range of determining between 0.5 and 10 ng 
of CTAP-III reactive material, the other components present in the plasma 
samples did not affect the assay system. 
CTAP-Ill, LA-PF4 and PTG all gave essentially identical curves of inhibition 
of anti-CTAP-lll-‘2Sl-CTAP-lll complex formation when plotted on a molar 
basis of the inhibitors. LA-PF, was shown previously to have the same biologic 
properties of CTAP-Ill (3) and the present results confirm the probable iden- 
tity of the two substances [3,13]. flTG does not have the biologic properties of 
CTAP-Ill and is slightly smaller in molecular weight [3,11,12,14], yet the two 
molecules are identical in antigenic reactivity with the anti-CTAP-III sera. It is 
likely that the two molecules are related, with flTG being derived from CTAP- 
Ill through proteolytic action [ 141. Therefore, the immunoassay of CTAP-Ill 
antigen in biologic samples would measure both PTG and CTAP-Ill. Also, we 
have shown that a.nti$TG antiserum- ‘2Sl-CTAP-lll complex formation is 
inhibited equivalently on a molar basis by’both PTG and CTAP-Ill. Thus, RlAs 
quantitating /3TG also include the amount of.CTAP-Ill present in the sample 
assayed. The relative content of these’tsvo p&&let factors in plasma and,other 
biologic specimens have not as yet been deteim’med. 
The additional sequence of CTAP-III compared to.PTG raises the question of 
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whether anti-CTAP-III sera may have an antibody population binding to an 
antigenic determinant of that sequence. No evidence was found to suggest that 
antiCTAP- specific antibodies were present. In the RIA system at low anti- 
serum dilutions (1 : 300) no differentiation of /3TG and CTAP-III inhibition 
curves was made. Also, no spurring of precipitin band formation was obtained 
in double immunodiffusion analyses of the large number of antiCTAP- sera 
tested. Reasons for the lack of specific antiCTAP- antibodies may be the fol- 
lowing. The CTAP-III may undergo proteolytic cleavage to PTG or smaller frag- 
ments at the immunization sites, or, the additional sequences of CTAP-III may 
be highly conserved and the rabbits may contain identical or very similar 
sequences and thus not recognize that portion of the molecule as sufficiently 
foreign to be immunogenic. Studies are in progress to prepare reagents which 
will differentiate CTAP-III from PTG. 
Of all the other substances tested for possible inhibitory capabilities in the 
antiCTAP- RIA, only the bovine FGF was active at about a lOO-fold greater 
weight ratio. Both CTAP-III and FGF exhibit many similar biologic properties 
[3] although their amino acid compositions are different. FGF may have an 
antigenic determinant amino acid sequence(s) similar to, but poorly cross- 
reactive with that of CTAP-III. Alternatively, the FGF preparations may con- 
tain a CTAP-III-like substance as a contaminant. 
The levels of CTAP-III reactive components in human plasma were deter- 
mined to have a mean value of 34 ng/ml for the 37 samples tested. This is 
similar to the values of /3TG in plasma of 30.5 ng/ml and 25.83 ng/ml obtained 
by Ludlam and Anderton [ 121 and Brown et al. [15], respectively. As noted 
by Dawes et al. [ 161 it is not yet clear how much of the /3TG (and CTAP-III) 
found in platelet-free plasma results from platelet release during venipuncture 
and sample preparation. The human serum concentration of the CTAP-III 
reactive component was at least 10 wg/ml, 250-fold greater than the human 
plasma value and representing the CTAP-III$TG components of the platelet 
released in the clotting process. It is interesting that other animal sera, except 
for the rhesus monkey serum, contained little or no reactivity in the RIA sys- 
tem. Thus, assuming that other species of animal have similar molecules with 
CTAP functions, the antiCTAP- sera are very specific for the human and 
monkey molecules. 
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